Fig. 1From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in ColombiaDecision tree model structure with two health states for prophylaxis with palivizumab to prevent the respiratory syncytial virus in childrenBack to article page